liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.
Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2014 (English)In: Addiction, ISSN 0965-2140, E-ISSN 1360-0443, Vol. 109, no 3, 440-449 p.Article in journal (Refereed) Published
Abstract [en]

AIM: To test the efficacy and safety of osmotic release oral system (OROS) methylphenidate (MPH) in doses up to 180 mg/day to treat attention deficit hyperactivity disorder (ADHD) and prevent any drug relapse in individuals with a co-diagnosis of ADHD and amphetamine dependence.

DESIGN: Randomized placebo-controlled 24-week double-blind trial with parallel groups design.

SETTING: Participants were recruited from medium security prisons in Sweden. The medication started within 2 weeks before release from prison and continued in out-patient care with twice-weekly visits, including once-weekly cognitive behavioural therapy.

PARTICIPANTS: Fifty-four men with a mean age of 42 years, currently incarcerated, meeting DSM-IV criteria for ADHD and amphetamine dependence.

MEASUREMENTS: Change in self-reported ADHD symptoms, relapse to any drug use (amphetamine and other drugs) measured by urine toxicology, retention to treatment, craving and time to relapse.

FINDINGS: The MPH-treated group reduced their ADHD symptoms during the trial (P = 0.011) and had a significantly higher proportion of drug-negative urines compared with the placebo group (P = 0.047), including more amphetamine-negative urines (P = 0.019) and better retention to treatment (P = 0.032).

CONCLUSIONS: Methylphenidate treatment reduces attention deficit hyperactivity disorder symptoms and the risk for relapse to substance use in criminal offenders with attention deficit hyperactivity disorder and substance dependence.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2014. Vol. 109, no 3, 440-449 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-104746DOI: 10.1111/add.12369ISI: 000331098300001PubMedID: 24118269OAI: oai:DiVA.org:liu-104746DiVA: diva2:698734
Available from: 2014-02-25 Created: 2014-02-25 Last updated: 2017-12-05

Open Access in DiVA

fulltext(325 kB)697 downloads
File information
File name FULLTEXT01.pdfFile size 325 kBChecksum SHA-512
2f12acf5b7b1d8b324acf3bab1c5add8dfd5c863966296e6dffc469a2262b4922be42d16f0809d084118575b52ce4dcde7aa7f811d8d344cc4a8afd19f324388
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Philips, Björn

Search in DiVA

By author/editor
Philips, Björn
By organisation
PsychologyFaculty of Arts and Sciences
In the same journal
Addiction
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 697 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 105 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf